Genomics and Machine Learning for In Vitro Sensitization Testing of Challenging Chemicals, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss how genomics and machine learning can provide a highly accurate method for both skin and respiratory sensitization assessment of chemicals, including “difficult-to-test” substances. Attendees will learn how customers across the chemical industry use the assays for skin and respiratory sensitization testing and get insights from industry partners from several applications and case studies.

Xtalks Life Science Webinars

This webinar will introduce the developmental phases of the GARD assays and discuss the technological origins of the observed high predictive performance, as well as how the assays help industries overcome their specific challenges in safety testing in a broad applicability domain

Predictive toxicology is a discipline that aims to proactively identify adverse human health and environmental effects in response to chemical exposure. GARD – Genomic Allergen Rapid Detection – is a next-generation, animal-free testing strategy framework for assessment and characterization of chemical sensitizers. The GARD platform integrates state-of-the-art technological components, including utilization of cell cultures of human immunological cells, omics-based evaluation of transcriptional patterns of endpoint-specific genomic biomarker signatures and machine learning-assisted classification-models.

To this end, the GARD platform provides accurate, cost effective and efficient assessment of skin and respiratory sensitizing capabilities of neat chemicals, complex formulations, mixtures and solid materials. GARD assays are successfully applied throughout the value chain of chemical and life science industries, including safety-based screening of candidates during preclinical research and development, monitoring of protocol changes and batch variations, monitoring of occupational health and for registration and regulatory approval.

This webinar will introduce the developmental phases of the GARD assays and discuss the technological origins of the observed high predictive performance, how the assays help industries overcome their specific challenges in safety testing in a broad applicability domain, and illustrate how GARD assays facilitate efficient decision-making in compliance with the principles of the 3Rs.

Join Andy Forreryd, PhD, SenzaGen AB and Henrik Johansson, PhD, Chief Scientist, SenzaGen AB in a live webinar on Wednesday, May 26, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Genomics and Machine Learning for In Vitro Sensitization Testing of Challenging Chemicals.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website